Pharmaceuticals News and Research

RSS

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009

New health care ads hit the airwaves

The onslaught of health care advertising continues, with new ads from MoveOn.org, Organizing for America, the medical industry and Americans United for Change.

3 Oct 2009

Update from BioCryst Pharmaceuticals regarding antiviral peramivir

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Office of the Secretary, Department of Health & Human Services (HHS) has issued "HHS Secretary's Declaration for the Use of the Public Readiness and Emergency Preparedness Act for the Influenza Antiviral Peramivir."

3 Oct 2009

American Kidney Fund to host national gala to support kidney care community

In celebration of people who are living with kidney disease, as well as the individuals and corporations who are working to improve the lives of kidney patients, the American Kidney Fund will host its first national gala, The Hope Affair, at the Newseum on October 6.

3 Oct 2009

CNN, TIME examine increasing antibiotic resistance

CNN examines a recent report by researchers that warns of increasing antibiotic resistance and appeals for governments to take action to develop new antibiotics to avert a health crisis.

3 Oct 2009

Auxilium Pharmaceuticals raises $115.7 million for general corporate purposes

Auxilium Pharmaceuticals, Inc. announced today that it has closed its previously announced public offering of 3,000,000 shares of its common stock at a price of $34.50 per share.

3 Oct 2009

NIH awards Titan $7.6M grant for Probuphine clinical development

Titan Pharmaceuticals, Inc today announced that the National Institutes of Health (NIH) has awarded a Research and Research Infrastructure Grand Opportunities grant to the company through the American Reinvestment and Recovery Act of 2009 (ARRA). The two year grant for Probuphine clinical development is expected to provide approximately $7.6 million, with the first year award of approximately $ 5.6 million now made available to Titan by the NIH.

3 Oct 2009

Angelman Syndrome Foundation increases grant award for 2009 for AS research

The Angelman Syndrome Foundation further solidified its dedication to research by increasing its grant award total to more than $1 million for 2009. Most recently, more than $988,000 in grants was awarded to six principle investigators, focusing on Angelman Syndrome (AS) research.

3 Oct 2009

Co-marketing partnership between Enzo Life Sciences and BioTek Instruments

Enzo Biochem, Inc. announced today a co-marketing partnership between its Enzo Life Sciences subsidiary, a world leader in non-radioactive probe technology, and BioTek Instruments, a privately held global leader in the development, manufacture and sale of microplate instrumentation for drug discovery and life science applications, involving powerful, integrated solutions for high throughput live cell analysis.

3 Oct 2009

Also in Global Health news: U.S. food aid declines; agriculture in Zimbabwe; U.S.-backed ITN network; reducing maternal mortality; DNDI expands; healthcare in Congo

Although U.S. food aid funding has increased by 53 percent over the last two years, a Government Accountability Office report on Wednesday said that during the same time period, the "amount of food delivered to address emergencies abroad fell 5 percent," the Washington Independent reports.

3 Oct 2009

SNM's joint session with CMOD on molecular imaging biomarkers in clinical research

SNM is collaborating with the International Partnership for Critical Markers of Disease (CMOD) during CMOD's 7th Annual Biomarkers and Surrogate Endpoints Symposium, Bethesda North Marriott Hotel and Conference Center, Bethesda, Md., Oct. 19th, 2009.

3 Oct 2009

China's State Intellectual Property Bureau grants patent for Aoxing Ganbao

Biostar Pharmaceuticals, Inc. ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has received a patent from China's State Intellectual Property Bureau for its Aoxing Ganbao product. The patent number is 551073.

2 Oct 2009

sNDA for Clonicel submitted to the FDA

Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

2 Oct 2009

Actavis' clients launch generic Atorvastatin in Spain

Actavis Group, the international generic pharmaceuticals company, today announced that its third-party sales division, Medis, has delivered 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market.

1 Oct 2009

HRA Pharma launches its new generation emergency contraceptive in Europe

HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.

1 Oct 2009

GSK allowed access to DiscoveRx' PathHunter ß-Arrestin parental cell lines and reagents

DiscoveRx Corp. announced today the signing of a global agreement with GSK, a leading pharmaceutical company, to provide access to its PathHunter™ ß-Arrestin parental cell lines, clones and associated reagents for use in GSK’s internal GPCR Screening and Profiling efforts.

1 Oct 2009

Catalyst Pharmaceutical Partners to continue development of CPP-109 drug

Catalyst Pharmaceutical Partners, Inc. today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction.

1 Oct 2009

First prescription foam formulation of benzoyl peroxide available

Onset Therapeutics, a specialty pharmaceutical company focused on dermatology, announced today the commercial availability of BenzEFoam (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide.

1 Oct 2009

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

1 Oct 2009

Addrenex submits a sNDA to the FDA for Clonicel

Sciele Pharma, Inc., a Shionogi company, and Addrenex Pharmaceuticals today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

1 Oct 2009